Japanease multi-center clinical trial to assess the inhibitory effects of branched chain amino acids on the recurrence after curative treatment of hepatocellular carcinoma
Not Applicable
- Conditions
- Hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000002330
- Lead Sponsor
- Ministry of Health, Labour and Welfare
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
1.Impregnated patient 2.Complication of ascites, edema and hepatic coma 3.Intrahepatic cholangiocarcinoma and metastatic liver tumor 4.Patient who is difficult to keep a diet therapy going 5.Insulin-treated diabetic patient 6.HCV negative patient after interferon therapy 7.HBsAg positive patient, heavy user of alcohol (more than 60g/day/ ethanol) 8.Patient who is in treatment with antiviral drug (Interferon, Peg-interforon, Ribavirin, etc) 9.Patient who is complicated with renal dysfunction including dialysis. 10.Patient who is associated with heavy heart, lung and hematological disorder, or others. 11.Inegible patient at a physician's discretion
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time to recurrence of hepatocellular carcinoma
- Secondary Outcome Measures
Name Time Method Survival time, Change of hepatic reserve, Change of lipid metabolisum and glucose tolerance, Change of nutritional state, etc